Northwestern University: Psychotic Disorders trials

The registry lists 10 Psychotic Disorders studies with Northwestern University as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 2 1Phase 3 2Phase 4 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effect of MMFS-202-302 on Cognitive Enhancement in SchizophreniaCompletedNCT02237235Phase 2Results posted
• Assessing the Effects of Fanapt® on Social Cognition in SchizophreniaTerminatedNCT01929889Phase 4Results posted
• High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to RisperidoneCompletedNCT00539071Phase 4Results posted
• Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00373672Phase 4Results posted
• Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?CompletedNCT00306475Phase 4Results posted
• Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance SyndromeCompletedNCT00288366Not applicableResults posted
• Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic ChangesTerminatedNCT00288353Phase 3Results posted
• Role Functioning Changes NOSTerminatedNCT02505022
• Serotonin 1A Agonists and Cognition in SchizophreniaCompletedNCT00178971Phase 3
• Improving Outcome in Schizophrenia Through Identification of Genetic Risk FactorsCompletedNCT00178932Not applicable